(Q35180490)

English

A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

11 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

18 July 2021

0 references

A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy (English)

1 reference

Europe PubMed Central

7 August 2017

diabetic retinopathy

10 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

monoclonal antibody

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

based on heuristic

inferred from title

postoperative complications

1 reference

3 September 2020

angiogenesis inhibitor

1 reference

5 November 2020

surgical blood loss

1 reference

18 July 2021

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Li-Quan Zhao

1

1 reference

Europe PubMed Central

7 August 2017

Huang Zhu

2

1 reference

Europe PubMed Central

7 August 2017

Pei-Quan Zhao

3

1 reference

Europe PubMed Central

7 August 2017

Yi-Qian Hu

4

1 reference

Europe PubMed Central

7 August 2017

language of work or name

0 references

publication date

27 January 2011

1 reference

Europe PubMed Central

7 August 2017

1 September 2011

11 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

18 July 2021

British Journal of Ophthalmology

12 references

Europe PubMed Central

7 August 2017

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

18 July 2021

95

1 reference

Europe PubMed Central

7 August 2017

9

1 reference

Europe PubMed Central

7 August 2017

1216-1222

1 reference

Europe PubMed Central

7 August 2017

copyright license

Creative Commons Attribution-NonCommercial

11 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

18 July 2021

on focus list of Wikimedia project

0 references

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Bevacizumab (Avastin) for the treatment of ocular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Overcoming the limitations of current meta-analysis of randomised controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21278146

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21278146

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21278146

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BJO.2010.189514

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35180490&oldid=1984295854"